Genmab: Oncology Specialist Breaks Out to Multi-Year High After Study Data - I Expect Further Price Increases!

Genmab (i.) is a European healthcare stock that combines the development of its own antibody technologies with strategic partnerships. A large portion of its ongoing revenue comes from royalties on established drugs like Darzalex. This financial buffer favorably sets Genmab apart from many loss-making competitors and largely finances the costly development from its own cash flow. Investors find a price driver in self-marketing. This trend was also evident in the ongoing week when the stock was able to make a leap to a multi-year high. The catalyst...